New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
10:00 EDTSKUL, ROYT, MDIUY, ICUI, GARS, CXO, BWLD, UNP, RSNAY, OMG, KSU, HP, EPB, CHH, BC, SYK, PKX, NBG, ICPT, GDP, DF, CRZO, ANFOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Buy from Hold at Stifel... Brunswick (BC) upgraded to Strong Buy from Market Perform at Raymond James... Buffalo Wild Wings (BWLD) upgraded to Equal Weight from Underweight at Morgan Stanley... Carrizo Oil & Gas (CRZO) upgraded to Outperform from Market Perform at BMO Capital... Choice Hotels (CHH) upgraded to Market Perform from Underperform at Wells Fargo... Concho Resources (CXO) upgraded to Buy from Accumulate at KLR Group... Dean Foods (DF) upgraded at Credit Suisse... El Paso Pipeline (EPB) upgraded to Neutral from Sell at Goldman... Garrison Capital (GARS) upgraded to Buy from Neutral at Ladenburg... Goodrich Petroleum (GDP) upgraded to Accumulate from Hold at KLR Group... Helmerich & Payne (HP) upgraded to Accumulate from Neutral at Global Hunter... ICU Medical (ICUI) upgraded at Raymond James... Intercept (ICPT) upgraded to Outperform from Market Perform at Leerink... Kansas City Southern (KSU) upgraded to Neutral from Underperform at Macquarie... Mediaset (MDIUY) upgraded to Overweight from Underweight at HSBC... National Bank of Greece (NBG) upgraded to Buy from Neutral at Citigroup... OM Group (OMG) upgraded to Overweight from Equal Weight at First Analysis... Pacific Coast Oil (ROYT) upgraded at Stifel... Posco (PKX) upgraded to Outperform from Neutral at Credit Suisse... RSA Insurance (RSNAY) upgraded to Neutral from Underperform at Credit Suisse... Skullcandy (SKUL) upgraded to Hold from Underperform at Jefferies... Stryker (SYK) upgraded to Buy from Hold at Needham... Union Pacific (UNP) upgraded to Outperform from Neutral at Macquarie.
News For ANF;BC;BWLD;CRZO;CHH;CXO;DF;EPB;GARS;GDP;HP;ICUI;ICPT;KSU;MDIUY;NBG;OMG;ROYT;PKX;RSNAY;SKUL;SYK;UNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 10, 2014
10:04 EDTANFOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded at Oppenheimer... American Eagle (AEO) downgraded to Neutral from Buy at B. Riley... BP (BP) downgraded to Neutral from Overweight at JPMorgan... Callon Petroleum (CPE) downgraded to Neutral from Buy at SunTrust... EP Energy (EPE) downgraded to Hold from Buy at Deutsche Bank... Eaton Vance (EV) downgraded at Sterne Agee... Ecopetrol (EC) downgraded to Underperform from Sector Perform at RBC Capital... General Mills (GIS) downgraded to Sector Perform from Outperform at RBC Capital... Genworth (GNW) downgraded to Market Perform from Outperform at Keefe Bruyette... MasTec (MTZ) downgraded to Hold from Buy at BB&T... Ocean Rig UDW (ORIG) downgraded to Neutral from Buy at Guggenheim... Performant Financial (PFMT) downgraded at Morgan Stanley... Petrobras (PBR) downgraded to Market Perform from Outperform at Cowen... R.R. Donnelley (RRD) downgraded to Hold from Buy at Benchmark Co.... Rex Energy (REXX) downgraded to Market Perform from Outperform at BMO Capital... Salix (SLXP) downgraded to Neutral from Buy at Mizuho... Siemens (SIEGY) downgraded to Neutral from Overweight at JPMorgan... Solazyme (SZYM) downgraded to Equal Weight from Overweight at Morgan Stanley... Stonegate Mortgage (SGM) downgraded to Market Perform at FBR Capital... Syngenta (SYT) downgraded to Neutral from Overweight at HSBC... ViaSat (VSAT) downgraded to Hold from Buy at Needham... Vistaprint (VPRT) downgraded to Neutral from Buy at SunTrust... Walter Investment (WAC) downgraded at Sterne Agee... WesBanco (WSBC) downgraded to Market Perform from Outperform at Keefe Bruyette... Whiting USA Trust II (WHZ) downgraded to Underperform at Raymond James... Wipro (WIT) downgraded to Sell from Buy at UBS... XOMA (XOMA) downgraded to Neutral from Buy at Ladenburg... Yanzhou Coal (YZC) downgraded to Sell from Hold at Deutsche Bank.
09:35 EDTDFActive equity options trading
Subscribe for More Information
09:34 EDTDFDean Foods expects butter fat declines at end of Q4
Subscribe for More Information
09:28 EDTDFDean Foods says butter has been in high demand recently
Export activities are decreasing and imports are increasing. Says cheese prices has held up better and will also converge due to pricing imbalance. Expects domestic raw milk costs to moderate as it exits 2014.
09:25 EDTDFDean Foods expects TruMoo to become a billion dollar brand
Subscribe for More Information
09:20 EDTDFOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTEPBKinder Morgan says ISS, Egan-Jones recommend approval of merger transactions
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
08:03 EDTDFDean Foods: Dairy commodity environment remains challenging
For Q4, the company expects raw milk costs will remain stubbornly high despite continued strong global production growth and waning demand. The company adds, "We don't expect much relief on raw milk costs until early 2015, but we do expect significant butterfat cost declines at the end of the fourth quarter. Industry volumes remain soft and we expect our fourth quarter volumes to be down low single digits, as compared to prior year, but with a continued improvement to net price realization. Further, as we move past our extended period of heavy plant closure activity and realize further costs reductions, we believe the rate of per-unit production and distribution costs will continue to decline and flatten from a year over year basis."
08:02 EDTDFDean Foods sees FY14 adjusted EPS (16c)-(6c), consensus (33c)
Sees FY14 adjusted EBITDA $193M-$208M; Sees FY14 free cash flow too end the year at approximately breakeven. Sees FY14 CapEx to be at low end of $150M-$175M guidance.
08:02 EDTDFDean Foods sees Q4 adjusted EPS 5c-15c, consensus (2c)
Subscribe for More Information
08:01 EDTDFDean Foods: This year has clearly been the most difficult operating environment
Subscribe for More Information
08:00 EDTDFDean Foods reports Q3 adjusted EPS (3c), consensus (13c)
Reports Q3 revenue $2.37B, consensus $2.35B
07:50 EDTANFAbercrombie & Fitch downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded to Abercrombie & Fitch Perform from Outperform. The firm downgraded the stock, citing lack of visibility, following the company's negative preannouncement. Target to $30 from $50.
07:14 EDTCXOHart Energy to hold a conference
Executive Oil Conference 2014 is being held in Midland, Texas on November 10-11.
06:34 EDTANFAbercrombie & Fitch downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
05:48 EDTANFU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
05:40 EDTANFAbercrombie & Fitch downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
November 8, 2014
20:32 EDTOMGOM Group shares 'could have a lot of upside', Barron's says
OM Group shares look cheap at current levels and "could have a lot of upside," Barron's argues in its 'Sizing Up Small Caps' column. The company has been returning capital to investors conservatively and could attract an activist investor, the paper adds. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use